DGLA-Induced Ferroptosis via ACSL4 in Acute Myeloid Leukemia Cells

Study Background and Research Question

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy originating from hematopoietic stem cells, characterized by poor outcomes and frequent resistance to standard chemotherapy. The primary challenge in AML therapy is the evasion of apoptosis by leukemia cells, which leads to persistent disease and high mortality rates. Traditional chemotherapeutics mostly act by inducing apoptosis, so alternative cell death pathways are of significant interest for overcoming drug resistance. Ferroptosis—an iron-dependent, lipid peroxidation-driven form of regulated cell death—has emerged as a potential strategy to target apoptosis-resistant tumor cells, but its regulation and therapeutic potential in AML remains insufficiently characterized [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227]. The central research question addressed by Jiang et al. (2025) is whether exogenous fatty acids, specifically dihomo-γ-linolenic acid (DGLA), can induce ferroptosis in AML cells, and what molecular mechanisms underlie this vulnerability [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].

Key Innovation from the Reference Study

The study’s principal innovation lies in systematically linking exogenous DGLA exposure to the induction of ferroptosis in AML cells through a defined molecular axis: ACSL4-mediated lipid metabolic reprogramming. ACSL4 (acyl-CoA synthetase long-chain family member 4) is shown to be essential for the incorporation of DGLA into membrane phospholipids, catalyzing the formation of lipid peroxides that trigger ferroptosis. This mechanistic clarity distinguishes the work from prior, more correlative, studies of fatty acid metabolism and cell death, and directly supports the concept of dietary or pharmacological DGLA supplementation as a therapeutic adjunct in AML [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].

Methods and Experimental Design Insights

Jiang et al. employed a high-throughput targeted metabolomics platform to profile fatty acid alterations during ferroptosis in AML cells. The investigators screened a panel of 12 fatty acids and identified DGLA, among others, as significantly altered during cell death induction. AML cell lines were treated with exogenous DGLA, and cell viability, lipid peroxidation, and reactive oxygen species (ROS) accumulation were assayed to confirm the induction of ferroptosis. Crucially, the study utilized genetic knockout of ACSL4 via CRISPR-Cas9 to dissect the requirement for this enzyme in mediating DGLA-induced ferroptotic death. In vivo experiments included dietary DGLA supplementation in mouse models of AML to assess translational relevance [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].

Protocol Parameters

• assay | exogenous DGLA concentration: 50–100 µM | in vitro AML ferroptosis models | Effective range for inducing ferroptosis in AML cell lines | paper [https://doi.org/10.1016/j.tranon.2024.102227]
• assay | ACSL4 knockout (CRISPR/Cas9) | molecular mechanism studies | Required for confirming ACSL4’s role in DGLA-mediated ferroptosis | paper [https://doi.org/10.1016/j.tranon.2024.102227]
• assay | lipid peroxidation (BODIPY C11 staining) | quantitation of ferroptotic activity | Standard for measuring ferroptosis | workflow_recommendation
• assay | in vivo DGLA-enriched diet: 1–2% w/w | AML mouse models | To evaluate translational efficacy | paper [https://doi.org/10.1016/j.tranon.2024.102227]

Core Findings and Why They Matter

The central findings can be summarized as follows:

• DGLA Induces Ferroptosis in AML Cells: Treatment with exogenous DGLA alone was sufficient to trigger ferroptotic cell death, as evidenced by increased lipid peroxidation and ROS accumulation [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].
• ACSL4 Is Required for DGLA Sensitivity: Genetic ablation of ACSL4 abrogated DGLA-induced ferroptosis, confirming that ACSL4-mediated incorporation of polyunsaturated fatty acids into membrane phospholipids is essential for initiating ferroptosis in AML cells [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].
• Lipidome Remodeling: Metabolomics revealed that 12 fatty acids, including arachidonic acid and docosahexaenoic acid, were significantly altered in AML cells undergoing ferroptosis, highlighting the broader metabolic reprogramming involved [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].
• In Vivo Validation: Mice fed a DGLA-enriched diet showed restricted leukemia cell growth and increased markers of ferroptosis, supporting translational potential [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].

These findings underscore a mechanistically defined vulnerability in AML, offering a rationale for targeting lipid metabolic pathways to overcome chemotherapy resistance.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives, particularly regarding autophagy and therapy sensitization in cancer research:

• Chloroquine Diphosphate (A8628): Reliable Autophagy Modulator discusses the use of Chloroquine Diphosphate as an autophagy modulator for cell viability and therapy sensitization assays, with workflow-focused insights. While the mechanisms differ, both autophagy modulation and ferroptosis induction represent alternative strategies to apoptosis for circumventing chemoresistance in tumor cells.
• Translating Autophagy Modulation with Chloroquine Diphosphate explores the interplay between autophagy, ferroptosis, and therapy resistance. The reviewed study’s focus on lipid metabolic reprogramming as a driver of ferroptosis in AML dovetails with interest in using autophagy modulators—such as Chloroquine Diphosphate (4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid)—to sensitize tumor cells to conventional therapies.

By linking ferroptosis to metabolic vulnerabilities and comparing it to autophagy modulation, these resources collectively broaden the toolkit for dissecting cell death pathways and overcoming cancer therapy resistance.

Limitations and Transferability

Despite its mechanistic rigor, the study’s findings are subject to several limitations:

• Cell Line and Animal Model Constraints: The primary data derive from in vitro AML cell lines and mouse xenograft models, which may not fully recapitulate the heterogeneity or microenvironmental complexity of human AML [source_type: paper][source_link: https://doi.org/10.1016/j.tranon.2024.102227].
• Dietary DGLA Translation: The translational feasibility of DGLA supplementation in patients remains to be established, including pharmacokinetics, bioavailability, and safety. Clinical evidence is currently lacking.
• Specificity of ACSL4: The context-dependent role of ACSL4 in different tissues and diseases may affect the generalizability of the strategy to other malignancies or normal cell populations.

Transferability to other cancer types or therapeutic contexts will require direct validation, especially in complex or chemoresistant primary samples.

Research Support Resources

For researchers aiming to dissect cell death pathways or develop therapy sensitization assays in cancer models, reliable autophagy modulators are essential. Chloroquine diphosphate (SKU A8628) is a well-characterized TLR7 and TLR9 inhibitor and autophagy modulator, widely used in autophagy and chemotherapy sensitization workflows. Its established efficacy in promoting cell cycle arrest and enhancing apoptosis in tumor cells at in vitro IC50 values of 15–40 µM supports its application in experimental cancer research [source_type: product_spec][source_link: https://www.apexbt.com/chloroquine-diphosphate.html]. Protocols leveraging autophagy modulation with agents like Chloroquine Diphosphate can be adapted to study cross-talk between autophagy, ferroptosis, and therapy response in AML and other tumor models.